Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera


Cite item

Full Text

Abstract

Aim. To evaluate the efficiency of interferon (IFN) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Subjects and methods. A total of 61 patients (41 with ET and 20 with PV) were examined. Prior to study enrolment, 44 (72%) patients with ET or PV received one or other therapy (aspirin was not taken into account). The mean Jak2V617F mutant allele at baseline was 23% (6—54%) in the patients with ET and 40% (11—88%) in those with PV. The median time from diagnosis to enrollment was 49 months. Results. The paper presents the clinical and molecular findings of long-term INF-α therapy in patients with ET or PV. The median follow-up was 52 months. Recombinant IFN-α2 showed its ability to induce complete hematologic remission (ET (76%), PV (70%)) and a complete molecular response. 22 (69%) out of 32 patients were noted to have a smaller number of cells with the Jak2V617F mutation. In the patients with PV and in those with ET, the relative reduction in the proportion of cells with the Jak2V617F mutant gene averaged 85% and 56% of the baseline values, respectively. There was a reduction in the proportion of cells expressing the Jak2V617F mutation in both the ET (from 12 to 2.2%; p=0.001) and PV (from 32.7% to 3.2%) groups (р=0.001). Ten (31%) patients achieved a deep molecular remission (≤2% Jak2V617F allele); among them, 5 patients were not found to have Jak2V617F mutation. The obtained molecular response remained in 7 of the 10 patients untreated for 11 to 86 months. The long-term treatment with IFN-α led to normalization of the morphological pattern of bone marrow in 5 of the 7 PV or ET patients. Conclusion. Significant molecular remissions achieved by therapy with recombinant interferon-α2 confirm the appropriateness of this treatment option in in the majority of patients with ET or PV.

References

  1. Spivak JL, Hasselbalch H. Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther. 2011;11(3):403-414. doi: 10.1586/era.11.10
  2. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P. Pegylated interferon2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072. doi: 10.1182/blood-2008-03-143537
  3. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya О, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053. doi: 10.1182/blood-2013-02-485888
  4. Хорошко Н.Д., Туркина А.Г., Журавлев В.С., Соколова М.А. , Семенова Е.А., Цветаева Н.В., Колпикова Л.А. «Место интерферона-а в коррекции гипертромбоцитоза у больных хроническими миелопролиферативными заболеваниями». Гематология и трансфузиология. 1999;4:43-45.
  5. Arellano-Rodrigo E, Alvarez-Larr´an A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169-175.
  6. Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106:2397-2405. doi: 10.1002/cncr.21900
  7. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: Final results of a phase 2 study. Cancer. 2007;110:2012-2018. doi: 10.1002/cncr.23018
  8. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037-2040. doi: 10.1182/blood-2006-03-009860
  9. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115(17):3842-3847. doi: 10.1002/cncr.24440
  10. Меликян А.Л., Туркина А.Г., Абдулкадыров К.М., Зарицкий А.Ю., Афанасьев Б.В., Шуваев В.А., Ломаиа Е.Г., Морозова Е.В., Байков В.В., Голенков А.К., Суборцева И.Н., Соколова М.А., Ковригина А.М., Мартынкевич И.С., Грицаев С.В., Судариков А.Б., Суханова Г.А., Иванова В.Л., Капланов К.Д., Константинова Т.С. ,Поспелова Т.И., Агеева Т.А., Шатохин Ю.В., Савченко В.Г. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз). Гематологияитрансфузиология. 2014;59(4):31-56.
  11. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles F. Pilot study of pegylated interferon alpha-2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003;51:81-86. doi: 10.1007/s00280-002-0533-4
  12. Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standart for oncology clinical trials Journal Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004. 22(14S(July 15 Supplement)): p.1
  13. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian J-J, Lengfelder E, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829-4833. doi: 10.1182/blood-2008-09-176818
  14. Абдуллаев А.О., Глинщикова О. А. Суслова С. А. Шадиева Н. Х. Колосова Л. Ю. Мещерякова Л. М. Вахрушева М. В. Судариков А. Б. Количественная оценка мутации v617f гена jak2 при хронических миелопролиферативных заболеваниях. Клиническая лабораторная диагностика. 2012;7:24-28.
  15. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc NatlAcadSeiUSA. 1977;74:5463-5467. doi: 10.1073/pnas.74.12.5463
  16. Spivak JL. The optimal management of polycythaemia vera. Br J Haematol. 2002;116:243-254. doi: 10.1046/j.1365-2141.2002.03287.x
  17. Kiladjian JJ, Rain JD, Bernard JF, Cambier N, Roussel M, Bellucci S, Chomienne C. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:417-421. doi: 10.1055/s-2006-942762
  18. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353:33-45. doi: 10.1056/NEJMoa043800
  19. Silver RT, Kiladjian JJ. Hasselbalch HC. Interferon and the treatment of essential thrombocythemia, polycythemia vera and myelofibrosis. Expert Rev Hematol. 2013;6(1):49-58. doi: 10.1586/ehm.12.69
  20. Larsen TS, Bjerrum OW, Pallisgaard N, Andersen MT, Møller MB, Hasselbalch HC. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol. 2008;87(10):847-850. doi: 10.1007/s00277-008-0498-4
  21. Kuriakose E, Vandris K, Wang YL, Chow W, Jones AV, Christos P, Cross N, Silver RT. Decreasein JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica. 2011;97(4):538-542. doi: 10.3324/haematol.2011.053348
  22. Larsen TS, Pallisgard N, Moller MB, Hasselbalch HC. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia. 2007;22:194-195. doi: 10.1038/sj.leu.2404861
  23. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89:2319-2327. doi:NOT
  24. Larsen TS, Møller MB, de Stricker K, Norgaard P, Samuelsson J, Marcher C. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology. 2009;14(6):331-334. doi: 10.1179/102453309X12473408860587
  25. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246-5249. doi: 10.1182/blood-2008-11-191544
  26. Соколова М.А., Цветаева Н.В., Суханова Г.А., Васильев С.А., Санатко М.Д., Хорошко Н.Д. Развитие синдрома Бадда—Киари у молодой больной в дебюте первичного миелофиброза (сублейкемического миелоза): клиническое наблюдение. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2010;1(3):
  27. Beer PA, Delhommeau F, Le Couédic JP, Dawson MA, Bareford ED, Kušec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Greenet AR. Two routes to leukemic transformation after JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2009;115:2891-2900. doi: 10.1182/blood-2009-08-236596
  28. Gilbert HS. Long term treatment of myeloproliferative disease with interferonalpha-2b: Feasibility and efficacy. Cancer. 1998;83:1205-1213. doi: 10.1002/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8
  29. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-a. Сancer. 2006;107(3):451-458. doi: 10.1002/cncr.22026
  30. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Lee-Yung Shih, Nagler A, Raynaud SD, Müller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koeffler HP. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115:2882-2890. doi: 10.1182/blood-2009-07-235119
  31. Larsen TS, Iversen KF, Hansen E, Mathiasen АВ, Marcher C, Frederiksen M, Hasselbalch HC. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37(9):1041-1045. doi: 10.1016/j.leukres.2013.06.012
  32. Соколова М.А., Хорошко Н.Д., Дмитриева М.Г., Журавлев В.С., Сагдиева Н.Ш., Егорова М.О., Моисеева Н.С., Нарейко М.В., Гемджян Э.Г., Сахибов Я.Д. Особенности диагностического подхода к эритроцитозам различного происхождения. Терапевтический архив. 2012;84(4):29-35.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies